The Editorial Office of Journal of Pharmacopuncture (JoP) received a report which is related to plagiarism issue by Leslie Lansman, the Global Permission Manager of SpringerNature. Accordingly, we began the inspection and found several plagiarized figures including Nature’s notifying.
The corresponding author had explained that “This article is not a research but a review which is collected in already existing research and has appropriate refereces.”
The authors of this article committed serious research misconduct. The editors of JoP are convinced an immediate, absolute retraction is needed.
Therefore, we retract this manuscript. Also, we inform researchers and medicine community that the contents and results of this paper is invalid.
We, the Editorial Board of Journal of Pharmacopuncture, seriously take this research ethics violation. We sincerely apologize to the reviewers, editors who devoted their time and endeavor to evaluate the article and medicine community.
Table 1.
The information of examined article
| Title | A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus |
| Authors | Mamo Gizaw1，Pandi Anandakumar1 (Corresponding author), Tolessa Debela2 |
| Institutions |
1 Biochemistry Unit, Department of Biomedical Sciences, College of Health Sciences, Arsi University，Asella, Ethiopia 2 Physiology Unit, Department of Biomedical Sciences, College of Health Sciences, Arsi University, Asella, Ethiopia |
| Publication | Journal of Pharmacopuncture 2017;20[4]:235-242 |
| DOI | https://doi.org/10.3831/KPI.2017.20.029 |
Table 2.
Discovered particulars of plagiarism
| Plagiarized figure in the article | Original source |
| Figure 1 | Figure 1.6 of “Investigating a potential role for irisin as a biomarker in the early detection of Alzheimer’s disease” [1] |
| Figure 2 | Figure of “Weight Loss: A New Star is Irisin” [2] |
| Figure 3 | Figure 4 of “Physiology and role of irisin in glucose homeostasis”[3] |
| Figure 4 | Figure 2 of “Physiology and role of irisin in glucose homeostasis” [3] |
| Figure 5 | Figure 8 of “FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity” [4] |
| Figure 6 | A figure of “Irisin inhibits hepatic glucone ogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes” [5] |
| Figure 7 | Figure 1 of “The p38- PGC-1 α-irisinbetatrophin axis”[6] |
References
- 1.Sabine Maria Bird. The University of Western Australia; 2018. Investigating a potential role for irisin as a biomarker in the early detection of Alzheimer's disease [dissertion] p. 402. DOI:10.4225/23/5b2af9560e3f7. [Google Scholar]
- 2.Brock G. Thomas. Weight Loss: A New Star is Irisin [Internet] Cayman Chemical; [cited 2020 March 26]. Available from: https://www.caymanchem.com/news/weight-loss-and-irisin/ [Google Scholar]
- 3.Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, et al. Physiology and role of irisin in glucose homeostasis. Nature. 2017;13:324–37. doi: 10.1038/nrendo.2016.221. DOI:10.1038/nrendo.2016.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Xiong XQ, Chen D, Sun HJ, Ding L, Wang JJ, Chen Q, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. BBA Molecular Basis of Disease. 2015;1852(9):1867–75. doi: 10.1016/j.bbadis.2015.06.017. DOI:10.1016/j.bbadis.2015.06.017. [DOI] [PubMed] [Google Scholar]
- 5.Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clinical Science. 2015;129(10):839–50. doi: 10.1042/CS20150009. DOI:10.1042/CS20150009. [DOI] [PubMed] [Google Scholar]
- 6.Sanchis-Gomar F, Perez-Quilis C. The p38-PGC-1α-irisin-betatrophin axis. Adipocyte. 2013;3(1):67–8. doi: 10.4161/adip.27370. DOI:10.4161/adip.27370. [DOI] [PMC free article] [PubMed] [Google Scholar]